Image

The China Pulmonary Thromboembolism Registry Study

The China Pulmonary Thromboembolism Registry Study

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Epidemiological data on pulmonary embolism (PE) in China needs to be updated and reported. The China Pulmonary Thromboembolism Registry Study (CURES) is designed to provide the cross-sectional spectrum and chronological trends of PE in China, as well as to reveal the intrinsic etiology and pathogenesis of the disease. The CURES is an ongoing large prospective multicenter registry, which was originally initiated in January 2009 via enrolling suspected or confirmed PE or PE with DVT (deep venous thrombosis) patients and assessed their in-hospital outcomes from 100 medical centers in the China PE-DVT network. As of July 2011, in order to determine the PE-relevant short-term outcomes, enrolled participants were followed-up for at least three months in a longitudinal manner. Since August 2016, with the launch and development of precision medicine research scheme in China, the main principle investigators of CURES decided to collect enrolled patients' blood samples with regular follow-ups every three or six months for at least two years (for long-term outcomes). The study protocol has been approved by the China-Japan Friendship Hospital ethics committee, and all collaborating centers received approvals from their local ethics committee. All patients provided written or verbal informed consent to their participation.

Eligibility

Patients aged 18 years or above who are admitted to the 100 participating medical centers

        with suspected PE or PE with DVT are potentially eligible participants and consecutively
        enrolled in this registry.
        Inclusion criteria:
          -  Objectively confirmed symptomatic PE or PE with DVT patients aged 18 years or above;
          -  Be able to provide written or verbal informed consent to participation.
        Exclusion criteria:
          -  Younger than 18 years;
          -  Participation in a therapeutic clinical trial with an unknown drug;
          -  Inability for at least three-month follow-up since July 2011;
          -  Suspected PE or PE with DVT patients admitted to the hospital whereas without
             confirmed medical evidence;
          -  Patients with a history of PE or DVT readmitted to the hospital for examination or
             treatment however with no evidence of acute episode or recurrence;
          -  Withdrawal or lack of informed consent.

Study details
    Pulmonary Embolism
    Deep Venous Thrombosis
    Venous Thromboembolism

NCT02943343

China-Japan Friendship Hospital

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.